Clinical and immunologic effects of component peptides in Allervax® cat

Philip S. Norman, Christopher F. Nicodemus, Peter Socrates Creticos, Robert A Wood, Peyton A. Eggleston, Lawrence M. Lichtenstein, Anne Kagey-Sobotka, David Proud

Research output: Contribution to journalArticle

Abstract

Peptides have been designed to be T cell tolerogenic for the principal allergens of the cat. These have been administered in several dosage programs to cat-sensitive patients in multicenter blinded studies. In contrast to proteins in standard extracts, IgE sensitization to peptides is an uncommon event. Pretreatment prick tests with peptides will identify the occasional sensitized patient. Other side reactions consist of allergic symptoms occurring on the day of injections. These become less severe with subsequent injections and are easily treatable with antihistamines or bronchodilators, depending on the symptoms. Treatment with cat peptides ameliorated symptoms that occur upon exposure to cats 1-6 or more weeks later. A 2-week course of 4 injections is the most effective of the regimens so far tried. T-cell-active peptides offer a promising low-risk alternative for specific treatment of respiratory allergies.

Original languageEnglish (US)
Pages (from-to)224-226
Number of pages3
JournalInternational Archives of Allergy and Immunology
Volume113
Issue number1-3
StatePublished - 1997

Fingerprint

Cats
Peptides
Injections
Hypersensitivity
T-Lymphocytes
Histamine Antagonists
Bronchodilator Agents
Allergens
Immunoglobulin E
Multicenter Studies
Therapeutics
Proteins

Keywords

  • Cat allergy
  • Immunotherapy
  • Peptides

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Clinical and immunologic effects of component peptides in Allervax® cat. / Norman, Philip S.; Nicodemus, Christopher F.; Creticos, Peter Socrates; Wood, Robert A; Eggleston, Peyton A.; Lichtenstein, Lawrence M.; Kagey-Sobotka, Anne; Proud, David.

In: International Archives of Allergy and Immunology, Vol. 113, No. 1-3, 1997, p. 224-226.

Research output: Contribution to journalArticle

Norman, PS, Nicodemus, CF, Creticos, PS, Wood, RA, Eggleston, PA, Lichtenstein, LM, Kagey-Sobotka, A & Proud, D 1997, 'Clinical and immunologic effects of component peptides in Allervax® cat', International Archives of Allergy and Immunology, vol. 113, no. 1-3, pp. 224-226.
Norman, Philip S. ; Nicodemus, Christopher F. ; Creticos, Peter Socrates ; Wood, Robert A ; Eggleston, Peyton A. ; Lichtenstein, Lawrence M. ; Kagey-Sobotka, Anne ; Proud, David. / Clinical and immunologic effects of component peptides in Allervax® cat. In: International Archives of Allergy and Immunology. 1997 ; Vol. 113, No. 1-3. pp. 224-226.
@article{2cc0f286a1994b1cb5844441e719de95,
title = "Clinical and immunologic effects of component peptides in Allervax{\circledR} cat",
abstract = "Peptides have been designed to be T cell tolerogenic for the principal allergens of the cat. These have been administered in several dosage programs to cat-sensitive patients in multicenter blinded studies. In contrast to proteins in standard extracts, IgE sensitization to peptides is an uncommon event. Pretreatment prick tests with peptides will identify the occasional sensitized patient. Other side reactions consist of allergic symptoms occurring on the day of injections. These become less severe with subsequent injections and are easily treatable with antihistamines or bronchodilators, depending on the symptoms. Treatment with cat peptides ameliorated symptoms that occur upon exposure to cats 1-6 or more weeks later. A 2-week course of 4 injections is the most effective of the regimens so far tried. T-cell-active peptides offer a promising low-risk alternative for specific treatment of respiratory allergies.",
keywords = "Cat allergy, Immunotherapy, Peptides",
author = "Norman, {Philip S.} and Nicodemus, {Christopher F.} and Creticos, {Peter Socrates} and Wood, {Robert A} and Eggleston, {Peyton A.} and Lichtenstein, {Lawrence M.} and Anne Kagey-Sobotka and David Proud",
year = "1997",
language = "English (US)",
volume = "113",
pages = "224--226",
journal = "International Archives of Allergy and Immunology",
issn = "1018-2438",
publisher = "S. Karger AG",
number = "1-3",

}

TY - JOUR

T1 - Clinical and immunologic effects of component peptides in Allervax® cat

AU - Norman, Philip S.

AU - Nicodemus, Christopher F.

AU - Creticos, Peter Socrates

AU - Wood, Robert A

AU - Eggleston, Peyton A.

AU - Lichtenstein, Lawrence M.

AU - Kagey-Sobotka, Anne

AU - Proud, David

PY - 1997

Y1 - 1997

N2 - Peptides have been designed to be T cell tolerogenic for the principal allergens of the cat. These have been administered in several dosage programs to cat-sensitive patients in multicenter blinded studies. In contrast to proteins in standard extracts, IgE sensitization to peptides is an uncommon event. Pretreatment prick tests with peptides will identify the occasional sensitized patient. Other side reactions consist of allergic symptoms occurring on the day of injections. These become less severe with subsequent injections and are easily treatable with antihistamines or bronchodilators, depending on the symptoms. Treatment with cat peptides ameliorated symptoms that occur upon exposure to cats 1-6 or more weeks later. A 2-week course of 4 injections is the most effective of the regimens so far tried. T-cell-active peptides offer a promising low-risk alternative for specific treatment of respiratory allergies.

AB - Peptides have been designed to be T cell tolerogenic for the principal allergens of the cat. These have been administered in several dosage programs to cat-sensitive patients in multicenter blinded studies. In contrast to proteins in standard extracts, IgE sensitization to peptides is an uncommon event. Pretreatment prick tests with peptides will identify the occasional sensitized patient. Other side reactions consist of allergic symptoms occurring on the day of injections. These become less severe with subsequent injections and are easily treatable with antihistamines or bronchodilators, depending on the symptoms. Treatment with cat peptides ameliorated symptoms that occur upon exposure to cats 1-6 or more weeks later. A 2-week course of 4 injections is the most effective of the regimens so far tried. T-cell-active peptides offer a promising low-risk alternative for specific treatment of respiratory allergies.

KW - Cat allergy

KW - Immunotherapy

KW - Peptides

UR - http://www.scopus.com/inward/record.url?scp=0030939933&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030939933&partnerID=8YFLogxK

M3 - Article

C2 - 9130529

AN - SCOPUS:0030939933

VL - 113

SP - 224

EP - 226

JO - International Archives of Allergy and Immunology

JF - International Archives of Allergy and Immunology

SN - 1018-2438

IS - 1-3

ER -